Chronic ONX-0914 Administration Alters Hippocampal Plasticity and Glutamate-Related Gene Expression

Study Background and Research Question

The ubiquitin-proteasome system (UPS) is essential for protein homeostasis in all eukaryotic cells, mediating the degradation of most intracellular proteins. Within this system, non-constitutive ("immune-type") proteasomes—characterized by the substitution of standard β subunits with their immunoproteasome-specific counterparts (β1i, β2i, β5i)—are best known for their roles in immune surveillance and inflammation. Recent evidence, however, points to their presence in the central nervous system (CNS), including neurons, astrocytes, and microglia, where their functions remain largely uncharacterized (source: paper). The reference study sought to determine how chronic inhibition of non-constitutive proteasomes using the selective LMP7 inhibitor ONX-0914 (PR-957) affects hippocampal synaptic plasticity and the expression of genes linked to glutamatergic signaling and memory processes.

Key Innovation from the Reference Study

The primary innovation lies in the selective, chronic pharmacological targeting of immunoproteasomes in vivo, specifically in the context of the CNS. Prior studies mainly used broad-spectrum proteasome inhibitors, which do not distinguish between constitutive and non-constitutive forms, often confounding results due to off-target effects. By employing ONX-0914, which selectively inhibits the β5i (LMP7) subunit of the immunoproteasome and spares the constitutive proteasome β5, the researchers could dissect the unique contributions of non-constitutive proteasomes to neuroplasticity (source: paper).

Methods and Experimental Design Insights

The investigators administered ONX-0914 chronically to mice and compared hippocampal responses to two standard long-term potentiation (LTP) induction protocols: tetanic stimulation and theta-burst stimulation (TBS). Electrophysiological recordings were performed in hippocampal slices to measure field-excitatory postsynaptic potentials (fEPSPs). Subsequent gene expression analyses focused on key regulators of synaptic plasticity and glutamatergic transmission. This dual-protocol approach enabled the researchers to differentiate the effects of immunoproteasome inhibition on distinct forms of LTP, which are associated with different types of memory and learning. Proper controls, including vehicle (DMSO) administration, ensured that observed effects were attributable to ONX-0914. For gene expression, quantitative analyses targeted markers implicated in synaptic function and neuroimmune signaling.

Protocol Parameters

• assay | ONX-0914 (PR-957) chronic injection | 10 mg/kg body weight, i.p. | murine hippocampal LTP and gene expression assays | Selective immunoproteasome targeting minimizes constitutive proteasome interference | paper
• assay | LTP induction by tetanic stimulation | 100 Hz, 1 s | fEPSP measurement in hippocampal slices | Assesses high-frequency-dependent synaptic potentiation | paper
• assay | LTP induction by theta-burst stimulation (TBS) | 10 bursts of 4 pulses at 100 Hz, 200 ms interval | fEPSP measurement in hippocampal slices | Models physiologic learning-related plasticity | paper
• assay | Gene expression profiling | RT-qPCR, target genes: synaptic plasticity/glutamate pathway | Post-LTP hippocampal tissue | Identifies molecular correlates of synaptic changes | paper
• assay | Vehicle control | DMSO, matched to ONX-0914 admin schedule | Confirms specificity of pharmacological effect | Standard protocol | workflow_recommendation

Core Findings and Why They Matter

Chronic ONX-0914 administration selectively impaired the induction of LTP by tetanic stimulation, evidenced by a significant reduction in fEPSP slope in treated animals relative to controls. In contrast, TBS-induced LTP was unaffected by immunoproteasome inhibition, indicating that non-constitutive proteasomes are specifically required for the high-frequency, tetanus-evoked form of synaptic potentiation (source: paper). Gene expression analyses revealed that ONX-0914 treatment altered the transcriptional profile of key genes involved in glutamatergic synaptic signaling and plasticity. These molecular changes paralleled the observed electrophysiological deficits, suggesting a mechanistic link between immunoproteasome activity, synaptic gene regulation, and memory-associated plasticity. The study substantiates an emerging paradigm in which immunoproteasome inhibition in the CNS does not simply recapitulate broad proteasome blockade but modulates neuroplasticity through discrete, context-dependent mechanisms. This has broad implications for the understanding of neuroimmune crosstalk and the development of therapies targeting neuroinflammation, cognitive dysfunction, and potentially neurodegenerative disease.

Comparison with Existing Internal Articles

Several internal resources expand on the intersection of immunoproteasome inhibition and CNS or immune function:

• Unveiling Immunoproteasome LMP7 Inhibition in CNS Plasticity offers an in-depth review of ONX-0914’s role in neuroimmune signaling and synaptic plasticity, connecting molecular findings to broader disease models. The present reference paper adds direct in vivo evidence for LMP7’s involvement in specific LTP forms, complementing the mechanistic perspective.
• Scenario-Driven Solutions for Reliable Immunoproteasome-Targeted Assays focuses on assay optimization and cytokine modulation in immune cells. While largely addressing autoimmune disease and cytokine production blockade, it underscores ONX-0914’s selectivity and workflow reproducibility, both relevant to the chronic CNS studies described here.
• Targeting Immunoproteasome for Neuroimmune Modulation bridges immunology and neuroscience, proposing that selective LMP7 inhibition can reveal new aspects of neuroimmune interface. The reference study provides direct electrophysiological and molecular validation for this concept.

These resources collectively illustrate the translational potential of ONX-0914 in both immunoproteasome inhibition in autoimmune disease and in CNS-focused research, such as memory and synaptic plasticity.

Limitations and Transferability

The study’s findings are specific to chronic ONX-0914 administration in murine models, and the precise translation to human CNS physiology remains to be established. The effects observed are context-dependent: only tetanus-induced LTP was impaired, while TBS-induced potentiation persisted, indicating that immunoproteasome roles are highly nuanced within the brain (source: paper). Furthermore, the molecular downstream pathways linking immunoproteasome inhibition to changes in synaptic gene expression require further elucidation. The chronic dosing regimen, species specificity, and experimental context (ex vivo hippocampal slices) may limit direct applicability to clinical scenarios. Nonetheless, the selective effect on LTP subtypes and gene expression expands the broader understanding of immunoproteasome function in neural circuits, aligning with evidence from arthritis research and diabetes research models where immune modulation is central.

Why this cross-domain matters, maturity, and limitations

The bridging of immunoproteasome inhibition from peripheral immune modulation (e.g., in cytokine production blockade and autoimmune disease) to CNS plasticity research is supported by the presence of non-constitutive proteasomes in neural tissue and their upregulation in neuroinflammatory contexts. However, the therapeutic implications for memory disorders or neurodegeneration remain exploratory, as robust clinical translation has not yet been established (source: paper).

Research Support Resources

Researchers aiming to replicate or extend these findings can source ONX-0914 (PR-957) (SKU A4011) for selective immunoproteasome inhibition in both CNS and immune cell models. APExBIO’s ONX-0914 is validated for potent LMP7 inhibition with high selectivity, supporting workflows in immunoproteasome inhibition in autoimmune disease, cytokine production blockade, and emerging CNS plasticity research (source: product_spec). For detailed methodologies and troubleshooting in immunoproteasome-targeted assays, consult scenario-driven guides and neuroimmune assay protocols referenced above.